:quality(90))
Every cancer target we find already knows its patient.
Most cancer programs fail in the clinic. Ours are designed not to.
Patient, target, and modality, defined together from day one, rooted in tumor biology captured in the operating room. That is where we begin.
:quality(90))
:quality(90)){kind=icon}
Native tumor biology. Captured.
A tumor's molecular profile begins changing the moment it is removed from the patient. That is why we standardize collection at every site: tumor and matched normal tissue, median cold ischemia time under 12 minutes, since 2002. A dataset that cannot be rebuilt retroactively.
Combined with clinical data from the same patient, this is human evidence to rely on when programs pick their targets.
:quality(90))
From insight to the clinic. Faster.
Rapid iteration between data analysis and target testing on our patient-derived materials compresses the discovery cycle. Weak programs die early. Strong ones advance on evidence.
IN-2503 moved from target idea to antibody hit in 10 months. That pace runs through all our programs. |
:quality(90))
:quality(90))
Clinically grounded. One loop.
Clinically grounded. One loop.
First, we measure.
Tumor biology captured in-situ, paired with clinical data from the same patient. Standardized across all collection sites.
- Matched tumor and normal tissue, and metastasis samples. Cold ischemia time median under 12 minutes
- Multi-omics profiling: genomics, transcriptomics, proteomics, phosphoproteomics, microRNAs
- ~300 clinical data points per patient, with follow-up out to 10 years
Clinically grounded. One loop.
Then, we stratify.
Proteomics-led multi-omics integration, applied at scale to identify the biology that separates patient populations.
- Multi-omics integration across patient cohorts
- Survival, expression, and pathway analysis to define clinically relevant subgroups
- Biomarker-informed patient selection and target prioritization
Clinically grounded. One loop.
Next, we test.
Target impact assessed in patient-derived models, so findings stay grounded in the biology they came from.
- Validation on fresh and FFPE patient tissue, and in in-house 3D patient-derived models
- IHC confirmation across representative patient subgroups
- Functional validation via knockdown, pharmacological inhibition, and monoclonal antibodies, confirming the target drives the phenotype
Clinically grounded. One loop.
Finally, we match.
Each target evaluated against the parameters that determine whether a modality works on it.
- Tumor-versus-normal selectivity and specificity
- Epitope accessibility, receptor density, and internalization rate
- Format matching across ADCs, bispecifics, and small molecules
:quality(90))
Risk reduced before the clinic. Program by program.
Patient, target, and modality, defined together from the start. Grounded in human evidence, just like every program in our pipeline.
:quality(90))
Company news and publicationsStay up to date with our latest news and publications.
:format(webp):quality(90))
:quality(90))
:quality(90))
Careers Help us shape the future of precision oncology.
One way or another, we can all be touched by the impact of cancer. That is why, for many of us, working at Indivumed is so much more than just a job. We are united by our shared purpose and passion: to improve cancer treatment for patients around the world.